Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer

Carlos L. Arteaga, Cristina I. Truica

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Emerging results from clinical trials with epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and, at best, modest to no clinical activity in a variety of epithelial tumors, including breast carcinomas. Although the EGFR is widely expressed in epithelial cancers, there is no evidence of frequent EGFR alterations at the DNA level in human tumors. This lack of molecular evidence to suggest a pathogenic role for the EGFR in breast cancer questions the notion that use of single-agent EGFR inhibitors in this disease is a viable therapeutic approach. The lack of selection of EGFR-dependent breast tumors into trials with EGFR inhibitors suggests the possibility that these were not true-negative studies. A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article.

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 3
StatePublished - Feb 1 2004

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Therapeutics
Neoplasms
Clinical Trials
DNA

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer. / Arteaga, Carlos L.; Truica, Cristina I.

In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 3, 01.02.2004, p. 3-8.

Research output: Contribution to journalReview article

@article{f541a5e3ddee44c1ac5f6d6a6c588277,
title = "Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer",
abstract = "Emerging results from clinical trials with epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and, at best, modest to no clinical activity in a variety of epithelial tumors, including breast carcinomas. Although the EGFR is widely expressed in epithelial cancers, there is no evidence of frequent EGFR alterations at the DNA level in human tumors. This lack of molecular evidence to suggest a pathogenic role for the EGFR in breast cancer questions the notion that use of single-agent EGFR inhibitors in this disease is a viable therapeutic approach. The lack of selection of EGFR-dependent breast tumors into trials with EGFR inhibitors suggests the possibility that these were not true-negative studies. A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article.",
author = "Arteaga, {Carlos L.} and Truica, {Cristina I.}",
year = "2004",
month = "2",
day = "1",
language = "English (US)",
volume = "31",
pages = "3--8",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer

AU - Arteaga, Carlos L.

AU - Truica, Cristina I.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Emerging results from clinical trials with epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and, at best, modest to no clinical activity in a variety of epithelial tumors, including breast carcinomas. Although the EGFR is widely expressed in epithelial cancers, there is no evidence of frequent EGFR alterations at the DNA level in human tumors. This lack of molecular evidence to suggest a pathogenic role for the EGFR in breast cancer questions the notion that use of single-agent EGFR inhibitors in this disease is a viable therapeutic approach. The lack of selection of EGFR-dependent breast tumors into trials with EGFR inhibitors suggests the possibility that these were not true-negative studies. A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article.

AB - Emerging results from clinical trials with epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and, at best, modest to no clinical activity in a variety of epithelial tumors, including breast carcinomas. Although the EGFR is widely expressed in epithelial cancers, there is no evidence of frequent EGFR alterations at the DNA level in human tumors. This lack of molecular evidence to suggest a pathogenic role for the EGFR in breast cancer questions the notion that use of single-agent EGFR inhibitors in this disease is a viable therapeutic approach. The lack of selection of EGFR-dependent breast tumors into trials with EGFR inhibitors suggests the possibility that these were not true-negative studies. A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article.

UR - http://www.scopus.com/inward/record.url?scp=2142708757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142708757&partnerID=8YFLogxK

M3 - Review article

C2 - 15052538

AN - SCOPUS:2142708757

VL - 31

SP - 3

EP - 8

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -